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Background: Although the incidence of toxoplasmosis is low in the United States, up to 6000 congenital cases
occur annually. In September 1998, the Centers for Disease Control and Prevention held a conference about
toxoplasmosis; participants recommended a survey of the toxoplasmosis-related knowledge and practices of
obstetrician-gynecologists and the development of professional educational materials for them.
Methods: In the fall of 1999, surveyswere mailed to a 2% random sample of American College of Obstetricians
andGynecologists(ACOG)membersandtoademographically representativegroupofACOGmembersknownas
the Collaborative Ambulatory Research Network (CARN). Responseswere not significantly different for the random
and CARN groups for most questions (p value shown when different).
Results: Among 768 US practicing ACOG members surveyed, 364 (47%) responded. Seven per cent (CARN
10%, random 5%) had diagnosedone or more case(s)of acute toxoplasmosis in the past year. Respondentswere
well-informed about how to prevent toxoplasmosis. However, only 12% (CARN 11%, random 12%) indicated
that a positive Toxoplasma IgM test might be a false–positive result, and only 11% (CARN 14%, random 9%)
were aware that the Food and Drug Administration sent an advisory to all ACOG members in 1997 stating
that some Toxoplasma IgM test kits have high false–positive rates. Most of those surveyed (CARN 70%, random
59%; c
2 p < 0.05) were opposed to universal screening of pregnant women.
Conclusions: Many US obstetrician-gynecologists will encounter acute toxoplasmosis during their careers, but
they are frequently uncertain about interpretation of the laboratory tests for the disease. Most would not recom-
mend universal screening of pregnant women.
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Although toxoplasmosis has a relatively low
incidence in the United States, it is still the third
leading cause of food-bornedeaths1, and estimates
range from 400 to 6000 congenital infections per
year1–4, which can lead to impaired vision, hearing
deficits and mental retardation. Obstetrician-
gynecologistsmay beconfrontedwith anumberof
issues regarding toxoplasmosis, including when to
test or screen pregnant women, how to interpret
laboratory test results, and how to manage patients
clinically. In September 1998, the Centers for
Disease Control and Prevention (CDC) held a
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Clinical study 23conference about toxoplasmosis to identify
research and prevention priorities4. Participants
attended from governmental, medical, academic
and industrial institutions. One of the reco-
mmendations of this conference was to determine
thetoxoplasmosis-relatedknowledgeandpractices
of obstetrician-gynecologists and to develop
professional education materials tailored to their
needs. As a result of this recommendation,
the CDC and the Department of Research of
the American College of Obstetrician and
Gynecologists (ACOG) collaborated to survey
obstetrician-gynecologists in the United States.
SUBJECTS AND METHODS
A survey instrument was developed by the Depart-
ment of Research of ACOG and CDC to collect
information from obstetrician-gynecologists
about their practice and patient characteristics,
knowledge about laboratory diagnostic tests,
laboratory screening and testing practices,
knowledge about clinical toxoplasmosis and
prevention of infection, and preventive counseling
practices. Questions were primarily in the
multiple-choice format. Input for development of
the survey was obtained from obstetrician-
gynecologists, laboratory workers, epidemiologists,
public health physicians, and infectious disease
physicians.
In the fall of 1999, the six-page questionnaire
wassentbytheDepartmentofResearch ofACOG
to a 2% random sample of ACOG members
(n = 786) and to another group of ACOG
members knownas the Collaborative Ambulatory
Research Network (CARN; n = 224). The
members of the network are practicing
obstetrician-gynecologists chosen to be
demographically representative of ACOG
members by age and sex who voluntarily
participate in surveys made periodically by the
college. A second mailing of the questionnaire
was made to nonrespondents 3 weeks after the
first. Questionnaires were compiled and data
enteredwitha uniqueID numberat ACOGhead-
quarters in Washington, DC. Only respondents
that practiced in the United States were included
in the analysis.
Response proportions for the random and
CARN groups were compared by the c2 test and
footnoted when the difference was statistically
sigificant (p < 0.05; see footnote in Table 2).
Combined responses only are given in the text
unless: (1) the CARN and random group
responses were statistically different, or (2) data are
presented in the text but not in Table 2. In these
two cases the CARN and random responses are
also given in the text. Ninety-five per cent
confidence intervals were calculated with
StatXact using the Clopper–Pearson method5.
Variances were similar for the CARN and
random group responses by the F-test, so 95%
confidence limits were calculated for the
combined groups. Data analyses were performed
with EpiInfo6 and SAS7 software, except for
responses to open-ended questions that were
categorized and tabulated by hand. Because there
were so many types of responses, the data for the
open-ended questions are summarized in the text
but are not shown in Table 2. Student’s t test was
used to compare the means for some of the demo-
graphic characteristics. Percentages are rounded to
thenearest1%inthetextandtothenearest0.1%in
the tables.
RESULTS
Response rate
Amongthe224CARNobstetrician-gynecologists
surveyed who practiced in the United States, 164
(73%) responded. Among the 786 randomly
selected obstetrician-gynecologists practicing
in the United States, 296 (38%) responded.
Ninety-six persons returned the questionnaire
without responding because they did not see
obstetric patients, leaving 364 responders for
analysis (CARN group 147, random group
217). Under the assumption that nonresponders
had the same percentage of foreign obstetrician-
gynecologists (4%) and physicians who did not see
obstetric patients as the responders (20%), the
adjusted response rate for the CARN and
randomly selected groups combined was 47%
(364/768). Not all respondents answered every
question.
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Themean age ofrespondentswas 45years forboth
the CARN and the random groups (Table 1). A
higherproportionofrespondentsfromtheCARN
group was female than from the random group
(49%vs. 38%,c2p = 0.04).Otherwise,theCARN
and random groups were similar by year of
completingresidency,regionoftheUnitedStates8,
and practice type (Table 1).
Diagnosis and laboratory testing
Overall, 91% responded that a positive Toxoplasma
gondii IgG test indicates that a woman has had
toxoplasmosis but does not determine when she
wasinfected(Table 2).Nearly half(48%)thoughta
positiveIgMtest meantthatawomanhadacquired
toxoplasmosiswithin thepast3months,6%within
the past 12 months, and 3% within the past 24
months. Only 12% indicated that a positive IgM
test could represent a false–positive result, and
only 11% of respondentswere aware that the FDA
had sent an advisory to physicians in 1997 stating
that there were problems with some commercial
T. gondii IgM test kits because of high false–
positive rates. Most (94%) indicated that, if a test
for IgM was positive, they would consult with a
specialist (for example, in infectious diseases or
perinatology). Overall, 7% of respondents indi-
cated that they had diagnosed one or more case(s)
of recently acquired infection with T. gondii in a
pregnant woman in 1998 (Table 2).
Clinical aspects
Most (87%) ACOG members were aware that
maternal T. gondii infections are not usually
symptomatic (Table 2). A majority (63%)
responded that risk of congenital disease is highest
when toxoplasmosis is contracted during the first
trimester, and 62% of members indicated that
congenital toxoplasmosis is less severe when
contracted in the last trimester (CARN group
57%, random group 65%; c2 p < 0.05). One per
cent of respondents indicated that all women with
positiveIgGtestsshouldbetreated.However,53%
of respondents indicated that all women with a
positive IgM test should be treated for toxo-
plasmosis (CARN group 47%, random group
57%; c2 p < 0.05).
Data are notshownin Table 2 for the following
median responses. Respondents indicated that a
woman with acute toxoplasmosis has about a 25%
chance of infecting her fetus (median response,
same result for random and CARN groups).
Overall, respondents indicated that the use of
spiramycin in a woman with acute toxoplasmosis
reduces her chance of infecting her fetus by 50%
(median response, same result for random and
CARN groups). Respondents also indicated that
70% (CARN group) to 75% (random group) of
congenitallyinfectedinfantsappearnormalat birth
(median responses).
Obstetricians and toxoplasmosis Jones et al.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 25
Characteristic
CARN1
(n = 147)
Random
(n = 217) p value*
Age (mean; years)
Year of completing
residency (mean)
Gender (percentage of
total)
Male
Female
Region of United States
(percentage of total)
Northeast
South
Midwest
West
Practice type
(percentage of total)
Solo
Multi-specialty group
University
OB/GYN partnership
or group
HMO
Military
Other
45
1985
51.0
49.0
20.4
31.7
24.6
23.3
16.3
15.6
13.6
46.9
2.7
1.4
3.4
45
1986
61.8
38.2
20.2
36.2
21.6
22.0
21.4
12.1
09.8
46.5
04.7
03.3
02.3
0.84
0.20
0.04
0.81
0.40
CARN, Collaborative Ambulatory Research Network;
*Comparison of CARN and random groups, Student’s t test for
means, c
2 for categorical data
Table 1 Demographic and practice-related character-
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Question or statement
CARN
yes or affirmative
Random
yes or affirmative
Total
yes or affirmative Total
95% CI
(%) N* Number (%) N* Number (%) N* Number (%)
Diagnosis and laboratory testing
A positive T. gondii IgG test indicates
a woman has been infected for how
long?
2 years
5 years
10 years
In the past, but cannot say when
Don’t know/other
A positive T. gondii IgM test indicates a
woman has been infected for how
long?**
Within 3 months
Within 12 months
Within 24 months
Recent, but cannot determine when
Don’t know
A positive T. gondii IgM test could be a
false–positive reaction
Aware FDA sent advisory to
physicians about false–positive
T. gondii IgM tests in 1997
Would consult a specialist if a T. gondii
IgM test returned positive
Diagnosed one or more acute cases of
toxoplasmosis in 1998
Clinical aspects
Maternal T. gondii infections are not
usually symptomatic
The risk of congenital disease is
highest if toxoplasmosis occurs in the
first trimester
Congenital disease is less severe if
toxoplasmosis occurs in the last
trimester†
All pregnant women with a positive
T. gondii IgG test should be treated
All pregnant women with a positive
T. gondii IgM test should be treated†
Screening for toxoplasmosis
Opposed or strongly opposed to
universal screening of pregnant
women for acute T. gondii infection†
143
143
143
143
143
147
147
147
147
147
147
147
108
135
147
145
145
142
141
141
0000 (0.0)
0002 (1.4)
0006 (4.2)
128 (89.5)
0011 (7.7)
64 (43.5)
0012 (8.2)
0003 (2.0)
70 (47.6)
0006 (4.1)
16 (10.9)
20 (13.6)
104 (96.2)
0013 (9.6)
0123 (83.7)
0093 (64.1)
0083 (57.2)
0002 (1.4)
66 (46.8)
99 (70.2)
215
215
215
215
215
217
217
217
217
217
217
216
157
198
216
217
216
215
214
211
0003 (1.4)
0003 (0.9)
0006 (2.8)
198 (92.0)
0008 (3.7)
112 (51.6)
0011 (5.1)
0008 (3.7)
112 (51.6)
0004 (1.8)
27 (12.4)
0019 (8.7)
146 (93.0)
0009 (4.5)
191 (88.4)
136 (62.7)
141 (65.3)
0003 (1.4)
122 (57.0)
0125 (59.2)
358
358
358
358
358
364
364
364
364
364
364
363
265
333
363
362
361
357
355
352
0003 (0.8)
0004 (1.1)
0012 (3.4)
327 (91.3)
0019 (5.3)
176 (48.2)
0023 (6.3)
0011 (3.0)
182 (50.0)
0010 (2.7)
43 (11.8)
39 (10.7)
250 (94.3)
0022 (6.6)
314 (86.5)
229 (63.3)
224 (62.0)
0005 (1.4)
188 (53.0)
0224 (63.6)
0.0, 2.4
0.0, 2.8
1.7, 5.8
87.9, 94.0
3.2, 8.2
43.0, 53.6
4.1, 9.3
1.5, 5.3
44.7, 55.3
1.3, 5.0
8.7, 15.6
7.8, 14.4
90.8, 96.8
4.2, 9.8
82.6, 89.8
58.1, 68.2
56.8, 67.1
0.5, 3.2
47.6, 58.3
57.7, 68.0
Continued over
Table 2 Responses from obstetrician-gynecologists in the United States to a survey about toxoplasmosis, 1999Obstetricians and toxoplasmosis Jones et al.
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Question or statement
CARN
yes or affirmative
Random
yes or affirmative
Total
yes or affirmative Total
95% CI
(%) N* Number (%) N* Number (%) N* Number (%)
When are pregnant women screened
for  toxoplasmosis in your practice?**
If they are considered high-risk
At every visit
At the initial exam
If the patient asks questions
If the patient mentions symptoms
Never
Prevention
In order to prevent toxoplasmosis it
is helpful for women to:**
Keep a cat completely outdoors
Wear gloves when changing litter
Wear gloves when gardening
Cover sand boxes
Wash hands after handling meat
Eat only well cooked meat
Not consume unpasteurized foods
How often do you counsel pregnant
women about preventing acute
toxoplasmosis?**
At every visit
At the initial exam
If the patient asks questions
If the patient mentions she was ill
If I consider the patient to be at
high risk
Never
Your counseling includes information
about**:
Eating undercooked foods
Handling raw foods
Handling cat litter
Inadvertent contact with cat feces
Gardening
How do you provide toxoplasmosis-
related information to pregnant
women?†
Verbally
Pamphlet
Other
146
146
146
146
146
146
145
145
146
145
146
146
146
145
145
145
145
145
145
140
140
141
140
139
144
144
144
91 (62.3)
02 (1.4)
035 (24.0)
055 (37.7)
067 (45.9)
020 (13.7)
083 (57.2)
109 (75.2)
116 (79.5)
111 (76.6)
127 (87.0)
133 (91.1)
089 (61.0)
03 (2.1)
095 (65.5)
064 (44.1)
11 (7.6)
049 (33.8)
05 (3.4)
117 (83.6)
106 (75.7)
141 (100.0)
133 (95.0)
100 (71.9)
140 (97.2)
14 (9.7)
01 (0.7)
211
211
211
211
211
211
213
217
216
213
216
217
217
212
212
212
212
212
212
207
204
207
203
201
215
216
216
145 (68.7)
00 (0.0)
048 (22.7)
070 (33.2)
102 (48.3)
023 (10.9)
105 (49.3)
176 (81.1)
162 (75.0)
148 (69.5)
185 (85.6)
193 (88.9)
144 (66.4)
02 (0.9)
139 (65.6)
088 (41.5)
16 (7.5)
083 (39.2)
06 (2.8)
172 (83.1)
157 (77.0)
207 (100.0)
198 (97.5)
130 (64.7)
205 (95.3)
026 (12.0)
05 (2.3)
357
357
357
357
357
357
358
362
362
358
362
363
363
357
357
357
357
357
357
347
344
348
343
340
359
360
360
236 (66.1)
2 (0.6)
083 (23.2)
125 (35.0)
169 (47.3)
043 (12.0)
188 (52.5)
285 (78.7)
278 (76.8)
259 (72.3)
312 (86.2)
326 (89.8)
333 (64.2)
05 (1.4)
234 (65.5)
152 (42.6)
27 (7.6)
132 (37.0)
11 (3.1)
289 (83.3)
263 (76.5)
348 (100.0)
331 (96.5)
230 (67.6)
345 (96.1)
040 (11.1)
06 (1.7)
60.9, 71.0
0.1, 2.0
19.0, 28.0
30.1, 40.2
42.1, 52.7
8.9, 15.9
42.7, 57.8
74.2, 82.8
72.1, 81.1
67.4, 76.9
82.2, 89.6
86.2, 92.7
59.0, 69.1
0.5, 3.2
60.4, 70.5
37.4, 47.9
5.0, 10.8
32.0, 42.2
1.6, 5.5
78.9, 87.1
71.6, 80.8
99.0, 100.0
94.0, 98.2
62.4, 72.6
93.5, 97.9
8.1, 14.8
0.6, 3.6
CARN, Collaborative Ambulatory Research Network; 95%  CI, 95% confidence interval; *N varies owing to different response rates for
each question; **respondents could check multiple answers for this questions;
†CARN response differs from random group response,
c
2 p < 0.05
Table 2 (Continued)Screening for toxoplasmosis
A majority (64%) of ACOG members were
opposedorstronglyopposedtouniversalscreening
of pregnant women for toxoplasmosis (CARN
group70%,randomgroup59%;c2p < 0.05;Table
2). When asked how often pregnant women in
their practice are screened for infection with
T. gondii 66% of ACOG members responded
‘when they are considered high risk’, 1%
responded ‘at every visit’, 23% responded ‘at the
initial exam’, 35% responded ‘if the patient asks
questions’, 47% responded ‘if the patient mentions
they have/had suggestive symptoms’, and 12%
responded ‘never’.
The following data for open-ended responses
are included here for completeness but are not
shown in Table 2. Open-ended responses were
collected to the question ‘whatpatientcharacteris-
tics would lead you to consider that a woman is at
high risk for toxoplasmosis?’ Among these
open-ended responses about risk, 67% (CARN
group 66%, random group 68%) of participants
specifically mentioned cat exposure, 12% (11%
CARN group, 13% random group) mentioned
cat-litter exposure, 30% (32% CARN group, 30%
random group) raw or undercooked meat
exposure,and9%(12%CARN group,7% random
group) gardening. Other less frequent responses
included doing veterinary work, living on a farm,
working with animals, living in a rural area,
working in a restaurant, hunting, abnormal fetal
ultrasound, fever/systemic illness, and history of
living in a foreign country.
In addition, open-ended responses were
recorded to a question that asked about the major
concerns ACOG members had with screening
pregnant women for toxoplasmosis. The most
frequent concerns were that screening would be
very costly and not cost-effective (44% overall;
44%CARN group,43% randomgroup),thatwith
screening there would be many false–positive
results or test results that are hard to interpret (29%
overall; 29% CARN group, 30% random group),
and that screening would create unnecessary
anxiety in patients (17% overall; 17% CARN
group, 17% random group). Some physicians (6%
overall; 5% CARN group, 7% random group)
thought that screening would lead to over-
treatment or that treatment is noteffective anyway
(3% overall; 3% CARN group, 3% random
group). When we asked about the cost of fully
screening a woman for toxoplasmosis, the median
response was $60 overall for an officevisit (CARN
group $50, random group $70), and for laboratory
testing costs the median response was $100 for
both the CARN and random groups.
Prevention
Overall, ACOG members were well-informed
about meat-, cat- and soil-related measures to
prevent transmission of toxoplasmosis and
indicated that they counsel women about these
measures (Table 2). Many respondents indicated
that they counsel pregnant women about toxo-
plasmosis at the initial examination (66%), when
the patient asks questions about toxoplasmosis
(43%), or when they consider the patient at high
risk for toxoplasmosis (37%). Nearly all (96%) of
the ACOG members surveyed indicated that
they provide toxoplasmosis-related prevention
information verbally, 11% indicated that they
provide pamphlets, and 2% indicated they use
other methods.
DISCUSSION
Inthis survey ofUS obstetrician-gynecologists,we
foundthat7%ofrespondentshaddiagnosedoneor
more case(s) of recently acquired toxoplasmosis in
a pregnant woman over a 1-year period. These
results imply that a considerable proportion of
obstetrician-gynecologists will encounter acute
toxoplasmosis in a pregnant woman during their
careers. Because treatment can help prevent severe
consequences of congenital infection, it is
important that obstetrician-gynecologists stay
informed about the diagnostic and clinical aspects
of toxoplasmosis.
Most respondents were aware that a positive
T. gondii IgG test indicates that a woman could
have been infected at any time in the past and that
the IgG test is not by itself an indication for
treatment. However, there was not a consistent
understanding among obstetrician-gynecologists
about the meaning of a positive T. gondii IgM test
in the diagnosis of acute toxoplasmosis. Because
numerous commercial T. gondii IgM tests have
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various sensitivity and specificity rates, interpret-
ation of results can be confusing. The largest
problem has been false–positive results with some
of the commercial IgM tests9,10. Because of the
problems with false–positive T. gondii IgM test
results, the FDA sent an advisory to physicians in
the United States in 1997 calling attention to the
limitations of these tests. Most obstetrician-
gynecologists surveyed were not aware of this
advisory. The T. gondii IgM test alone should not
be used as a screening test for acute T. gondii
infection. The T. gondii IgG test should be used
first, because 86% of women of child-bearing age
do not have evidence of prior exposure to
T. gondii11, and the IgG test can be used to rule out
infection for most women. When the IgG test is
positive, an IgM test should be ordered to
determine whether the infection is relatively
recent. If the IgM test is negative, then no further
testing is required. If the IgM test is also positive,
thewomanmay havebeen infectedwithin thepast
18 months.In this case additionaltesting should be
done at a reference laboratory to rule out a
false–positive IgM test and to determine whether
the infection is likely to have occurred during the
pregnancy10. Incorrect interpretation of false–
positive T. gondii IgM test results could lead to
inappropriate use of antiparasitic medication in
pregnant women and possibly unnecessary
interruption of pregnancy.
With regard to clinical symptoms of toxo-
plasmosis, most oftherespondentswereaware that
maternal T. gondii infections are not usually
symptomatic. Studies indicate that mild symptoms
such as lymphadenopathy,fever and fatigue occur
in 10–20% of immunocompetent adults and
generally resolve without treatment in weeks to
months12. However, there was less certainty
among the obstetrician-gynecologists surveyed
about the risk of congenital disease relative to the
trimester when a woman acquires an infection
with T. gondii. The risk of congenital infection is
lowest (10–25%) when acute maternal infection
occurs during the first trimester and highest (60%
or higher) when acute maternal infection occurs
duringthethird trimester13. However, theseverity
ofdisease isworsewheninfectionisacquiredinthe
first trimester13,14. The overall risk of congenital
infection from acute T. gondii infection during
pregnancy is 20–50%13.
Respondents tended to indicate that treatment
of acute T. gondii infection during pregnancy with
spiramycin reduces the chance of congenital
infection by about 50%. Some researchers have
foundthattreatmentduringpregnancyreducesthe
chance of congenital infection by up to 60%15–18.
However, others have stated that, because
there were no directly comparable control
groups in studies of treated women that found a
reduction in congenital infection, it is unclear
whether prenatal treatment in women with
toxoplasmosis reduces congenital transmission of
T. gondii19. Respondents also tended to indicate
that most congenitally infected infants appear
normal at birth, even though many will develop
clinicalproblemslater ifuntreated.Thisresponse is
consistent with the literature2,20–22.
A majority of the obstetrician-gynecologists
surveyed were opposed to universal screening of
pregnant women in the United States for T. gondii
infection. However, from the survey there are
no consistent criteria that emerge for when
obstetrician-gynecologists should test pregnant
women for acute T. gondii infection. Some
respondents indicated that they test women at the
initial prenatal examination; others indicated that
they test a woman when she asks questions about
toxoplasmosis or is considered to be at risk
for acute infection. Interestingly, very few
respondents (12%) indicated that they never test
pregnant women for acute T. gondii infection.
The obstetricians surveyed gave a median
response of a $60 cost for an office visit and a $100
cose for laboratory testing to fully screen a woman
for toxoplasmosis. We have foundthat costs range
from $50 to $100 each for IgG and IgM testing at
commercial laboratories and that a complete
confirmatory testing evaluation at a reference
laboratory costs $300–400.
The obstetrician-gynecologists surveyed were
well-informed about measures to prevent
transmission of T. gondii to pregnantwomen. This
result is particularly encouraging insofar as several
studies, although not carried out in the United
States, have shown that primary prevention
messages are associated with improvement in
Toxoplasma-related health behaviors23 and a
Obstetricians and toxoplasmosis Jones et al.
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during pregnancy compared to historic
controls24–26. Nearly all ACOG members
responded that they provide verbal counseling to
pregnant women, although 11% indicated that
they also provide pamphlets.
One area in which there was a wider range of
responses from those surveyed had to do with care
of cats. Always keeping a cat indoors greatly
reducesthe chancesthat a cat will acquire T. gondii
infection because the cat is less likely to ingest prey
that is infected with T. gondii. Changing the cat
litter box daily helps prevent transmission of
T. gondii, because, even under the best conditions
(warm, moist environment), the oocysts excreted
by cats take 1–5 days to sporulate and become
infectious27.
A limitation of the study is the low (38%)
responserate amongtherandomgroup.However,
the response rate was much better in the CARN
group(73%),and responsestomost questionswere
very similar for the two groups. Nevertheless,
response to the question ‘should all pregnant
women with a positive IgM test be treated?’ was
higher for the random group (57%) than for the
CARN group (47%), and response to thequestion
about being ‘opposed to universal screening of
pregnant women for acute T. gondii infection’ was
higher for the CARN group (70%) than for the
random group (59%). The responses to these two
questions may indicate that persons in the CARN
grouparemore knowledgeableaboutthepitfallsof
false–positive Toxoplasma IgM tests and more
concerned about the possible adverse conse-
quences of universal screening. Because persons in
the CARN group volunteer to participate, they
may be more knowledgeable about these issues.
Non-response bias could also explain the differ-
ences.
Overall, it is apparent from our survey that
a considerable proportion of ACOG obstet-
rician-gynecologists in the United States will
encounter acute infection with T. gondii in their
practice. Continuingeducationmaterials are being
developed by ACOG and CDC based on this
survey. Future research should focus on how
effective continuing education materials are at
improving knowledge about toxoplasmosis.
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